RE:Attralus buys in brain shuttle tech to cross BBB These transferrin receptor-based BBB transport technologies are getting quite numerous. In addition to Denali, there are
They all use different technologies to deliver drugs across the BBB but all of their technologies use the same receptor, the transferrin receptor (TfR). Denali uses its F-Star structures, JCR has J-Brain Cargo, and Ossianix uses TXP1, which is based on single domain VNAR antibodies, which, in turn, is based on the
shark Immunoglobulin Novel Antigen Receptor (IgNAR).
We could get into the weeds really quickly with all of these, and maybe we'll go there someday if the need arises, but they all share the same BBB target, the transferrin receptor. xB3 has always shown superior delivery capabilities with the LRP-1 receptor than these other technologies do with the transferrin receptor.
Whether xB3 competes well with with these TfR technologies or not, the Denali and JCR TfR technologies are far more advanced than xB3, with JCR actually having a J-Cargo LSD drug (Hunter syndrome) approved in the Japanese market and with the possibility of having it soon approved by the FDA. That's the price paid by Bioasis for doing nothing for so long.
The development of several TfR technologies likely happened because each technology is patented by its owner, so to use the TfR, different technologies are required to avoid patent infringements. The trouble is, of course, if xB3 is the best technology, how come nobody else is developing other technologies to use the LRP-1 receptor? (As least not that I've ever seen.) Is it recognized by all of the planet except for Bioasis and its shareholders that nobody wants xB3, or anything to do with the LRP-1 Receptor?
As I have said, Bioasis needs to tell shareholders whether xB3 is a worthy competitor to the TfR technologies.
jd